OmniAb(OABI) - 2023 Q4 - Earnings Call Transcript

Matthew Foehr Yes, Joe. Look, I mean, we always -- as you pointed out, we report our numbers net of attrition for active partners, active programs and active clinical and approved products. Largely because we find that gives the best clarity on where the business stands and where it's headed. Attrition, of course, is very natural, very expected in pharmaceutical discovery and development, it can be different stage to stage. And as we're building up our experience with programs and our portfolio, there are s ...